Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: The evolution of anti-TNF therapy in rheumatic disease: experience, insights and advances

Highly Accessed Review

Infliximab: 12 years of experience

Josef S Smolen* and Paul Emery

  • * Corresponding author: Josef S Smolen

Arthritis Research & Therapy 2011, 13(Suppl 1):S2  doi:10.1186/1478-6354-13-S1-S2


  • Last 30 days: 115 accesses
  • Last 365 days: 1749 accesses
  • All time: 9951 accesses